Australia’s TGA To Stamp Out Clinical Evidence Mistakes By Industry
Executive Summary
The Australian Therapeutic Goods Administration is attempting to clarify its expectations on clinical evidence requirements for medical devices to stop the many errors companies are making in their submissions for market authorization.
You may also be interested in...
Australia’s 'Unrealistic' Randomized Controlled Trial Proposal Comes Under Fire
Industry is not entirely happy with the Therapeutic Goods Administration’s proposed guidelines on clinical evidence requirements.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.